

# Anthony Tak-Cheung Chan

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5704051/anthony-tak-cheung-chan-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

373  
papers

23,230  
citations

83  
h-index

142  
g-index

417  
ext. papers

26,678  
ext. citations

5.5  
avg, IF

6.62  
L-index

#	Paper	IF	Citations
373	Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): An update on 26 trials and 7080 patients.. <i>Clinical and Translational Radiation Oncology</i> , <b>2022</b> , 32, 59-68	4.6	2
372	Shift detection discrepancy between ExacTrac Dynamic system and cone-beam computed tomography.. <i>Journal of Applied Clinical Medical Physics</i> , <b>2022</b> , e13567	2.3	1
371	Opportunities and challenges in combining immunotherapy and radiotherapy in head and neck cancers.. <i>Cancer Treatment Reviews</i> , <b>2022</b> , 105, 102361	14.4	0
370	The effect on tumour control probability of using AXB algorithm in replacement of AAA for SBRT of hepatocellular carcinoma located at lung-liver boundary region. <i>BJR/Open</i> , <b>2021</b> , 3, 20210041	1.4	0
369	Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 840-859	2.2	42
368	Dynamic Changes of Post-Radiotherapy Plasma Epstein-Barr Virus DNA in a Randomized Trial of Adjuvant Chemotherapy Versus Observation in Nasopharyngeal Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 2827-2836	12.9	2
367	Nasopharyngeal carcinoma: an evolving paradigm. <i>Nature Reviews Clinical Oncology</i> , <b>2021</b> , 18, 679-695	19.4	28
366	Whole-genome profiling of nasopharyngeal carcinoma reveals viral-host co-operation in inflammatory NF- $\kappa$ B activation and immune escape. <i>Nature Communications</i> , <b>2021</b> , 12, 4193	17.4	10
365	Durability of the parotid-sparing effect of intensity-modulated radiotherapy (IMRT) in early stage nasopharyngeal carcinoma: A 15-year follow-up of a randomized prospective study of IMRT versus two-dimensional radiotherapy. <i>Head and Neck</i> , <b>2021</b> , 43, 1711-1720	4.2	2
364	The effect of the magnetic fields from three different configurations of the MRIGRT systems on the dose deposition from lateral opposing photon beams in a laryngeal geometry DA Monte Carlo study. <i>Radiation Medicine and Protection</i> , <b>2021</b> , 2, 103-103	2	
363	The expanding universe of checkpoint inhibitors for nasopharyngeal cancer. <i>Nature Medicine</i> , <b>2021</b> , 27, 1512-1513	50.5	2
362	Analysis of Hepatocellular Carcinoma Stereotactic Body Radiation Therapy Dose Prescription Method Using Uncomplicated Tumor Control Probability Model. <i>Advances in Radiation Oncology</i> , <b>2021</b> , 6, 100739	3.3	1
361	Prospective Randomized Phase II Study of Stereotactic Body Radiotherapy (SBRT) vs. Conventional Fractionated Radiotherapy (CFRT) for Chinese Patients with Early-Stage Localized Prostate Cancer.. <i>Current Oncology</i> , <b>2021</b> , 29, 27-37	2.8	
360	NPC-0501 trial on the value of changing chemoradiotherapy sequence, replacing 5-fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma. <i>Cancer</i> , <b>2020</b> , 126, 3674-3688	6.4	13
359	Sequencing Analysis of Plasma Epstein-Barr Virus DNA Reveals Nasopharyngeal Carcinoma-Associated Single Nucleotide Variant Profiles. <i>Clinical Chemistry</i> , <b>2020</b> , 66, 598-605	5.5	5
358	Recent Advances in the Development of Biomarkers and Chemoradiotherapeutic Approaches for Nasopharyngeal Carcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2020</b> , 40, 1-11	7.1	2
357	Germline Polymorphisms and Length of Survival of Nasopharyngeal Carcinoma: An Exome-Wide Association Study in Multiple Cohorts. <i>Advanced Science</i> , <b>2020</b> , 7, 1903727	13.6	4

356	Integrating postradiotherapy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy. <i>Annals of Oncology</i> , <b>2020</b> , 31, 769-779	10.3	27
355	The emerging data on choice of optimal therapy for locally advanced nasopharyngeal carcinoma. <i>Current Opinion in Oncology</i> , <b>2020</b> , 32, 187-195	4.2	6
354	Network-meta-analysis of chemotherapy in nasopharyngeal carcinoma (MAC-NPC): An update on 8,221 patients.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 6523-6523	2.2	7
353	Targeting the polycomb repressive complex-2 related proteins with novel combinational strategies for nasopharyngeal carcinoma. <i>American Journal of Cancer Research</i> , <b>2020</b> , 10, 3267-3284	4.4	3
352	Patient-specific quality assurance using machine log files analysis for stereotactic body radiation therapy (SBRT). <i>Journal of Applied Clinical Medical Physics</i> , <b>2020</b> , 21, 179-187	2.3	11
351	Tumor Suppression of Ras GTPase-Activating Protein RASA5 through Antagonizing Ras Signaling Perturbation in Carcinomas. <i>IScience</i> , <b>2019</b> , 21, 1-18	6.1	6
350	Nasopharyngeal carcinoma. <i>Lancet, The</i> , <b>2019</b> , 394, 64-80	4.0	747
349	Complementary roles of MRI and endoscopic examination in the early detection of nasopharyngeal carcinoma. <i>Annals of Oncology</i> , <b>2019</b> , 30, 977-982	10.3	29
348	Cost-effectiveness of Screening for Nasopharyngeal Carcinoma among Asian American Men in the United States. <i>Otolaryngology - Head and Neck Surgery</i> , <b>2019</b> , 161, 82-90	5.5	4
347	Distinguishing early-stage nasopharyngeal carcinoma from benign hyperplasia using intravoxel incoherent motion diffusion-weighted MRI. <i>European Radiology</i> , <b>2019</b> , 29, 5627-5634	8	21
346	Methylation analysis of plasma DNA informs etiologies of Epstein-Barr virus-associated diseases. <i>Nature Communications</i> , <b>2019</b> , 10, 3256	17.4	30
345	Stereotactic body radiotherapy (SBRT) versus conventional fractionated intensity-modulated radiotherapy (CF-IMRT) for patients with early-stage localized prostate cancer: One-year late toxicity results from a prospective randomized phase II study.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 6707-6717	2.2	
344	Afatinib versus methotrexate as second-line treatment for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) progressing on or after platinum-based therapy: LUX-Head & Neck 3 phase III trial.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 6024-6024	2.2	1
343	Extranodal extension is a criterion for poor outcome in patients with metastatic nodes from cancer of the nasopharynx. <i>Oral Oncology</i> , <b>2019</b> , 88, 124-130	4.4	23
342	The Use of Post-ablation Stimulated Thyroglobulin in Predicting Clinical Outcomes in Differentiated Thyroid Carcinoma - What Cut-off Values Should We Use?. <i>Clinical Oncology</i> , <b>2019</b> , 31, e11-e20	2.8	2
341	Induction Chemotherapy plus Concurrent Chemoradiotherapy in Endemic Nasopharyngeal Carcinoma: Individual Patient Data Pooled Analysis of Four Randomized Trials. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 1824-1833	12.9	78
340	MR Imaging Criteria for the Detection of Nasopharyngeal Carcinoma: Discrimination of Early-Stage Primary Tumors from Benign Hyperplasia. <i>American Journal of Neuroradiology</i> , <b>2018</b> , 39, 515-523	4.4	24
339	Efficacy, Safety, and Pharmacokinetics of Axitinib in Nasopharyngeal Carcinoma: A Preclinical and Phase II Correlative Study. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 1030-1037	12.9	26

338	Prospective evaluation of plasma Epstein-Barr virus DNA clearance and fluorodeoxyglucose positron emission scan in assessing early response to chemotherapy in patients with advanced or recurrent nasopharyngeal carcinoma. <i>British Journal of Cancer</i> , <b>2018</b> , 118, 1051-1055	8.7	13
337	Epigenomic characterization of a p53-regulated 3p22.2 tumor suppressor that inhibits STAT3 phosphorylation via protein docking and is frequently methylated in esophageal and other carcinomas. <i>Theranostics</i> , <b>2018</b> , 8, 61-77	12.1	21
336	Epstein-Barr Virus-Induced Epigenetic Pathogenesis of Viral-Associated Lymphoepithelioma-Like Carcinomas and Natural Killer/T-Cell Lymphomas. <i>Pathogens</i> , <b>2018</b> , 7,	4.5	11
335	Association Between Serum Folate Level and Toxicity of Capecitabine During Treatment for Colorectal Cancer. <i>Oncologist</i> , <b>2018</b> , 23, 1436-1445	5.7	4
334	Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study). <i>Oral Oncology</i> , <b>2018</b> , 77, 16-21	4.4	112
333	Nasopharyngeal carcinoma: relationship between invasion of the prevertebral space and distant metastases. <i>European Archives of Oto-Rhino-Laryngology</i> , <b>2018</b> , 275, 497-505	3.5	6
332	Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1412-1418	2.2	185
331	Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , <b>2018</b> , JCO2018777847	2.2	90
330	Preclinical evaluation of ribociclib and its synergistic effect in combination with alpelisib in non-keratinizing nasopharyngeal carcinoma. <i>Scientific Reports</i> , <b>2018</b> , 8, 8010	4.9	18
329	Sequencing-based counting and size profiling of plasma Epstein-Barr virus DNA enhance population screening of nasopharyngeal carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2018</b> , 115, E5115-E5124	11.5	75
328	Retrospective study of the prevalence and progression of monoclonal gammopathy in HIV positive versus HIV negative patients. <i>Hematological Oncology</i> , <b>2017</b> , 35, 64-68	1.3	4
327	Incorporating albumin-bilirubin grade into the cancer of the liver Italian program system for hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2017</b> , 32, 221-228	4	39
326	Exome and genome sequencing of nasopharynx cancer identifies NF- $\kappa$ B pathway activating mutations. <i>Nature Communications</i> , <b>2017</b> , 8, 14121	17.4	163
325	Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma - clinical application of health-related quality-of-life data. <i>BMC Cancer</i> , <b>2017</b> , 17, 8	4.8	25
324	Biologics and biosimilars: what, why and how?. <i>ESMO Open</i> , <b>2017</b> , 2, e000180	6	12
323	Investigational drugs for nasopharyngeal carcinoma. <i>Expert Opinion on Investigational Drugs</i> , <b>2017</b> , 26, 677-685	5.9	15
322	Identifying an early indicator of drug efficacy in patients with metastatic colorectal cancer-a prospective evaluation of circulating tumor cells, 18F-fluorodeoxyglucose positron-emission tomography and the RECIST criteria. <i>Annals of Oncology</i> , <b>2017</b> , 28, 1576-1581	10.3	15
321	Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,	9.7	31

320	What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 498-505	2.2	176
319	Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 513-522	59.2	338
318	Retrospective study of the incidence and patterns of arterial and venous thrombosis in Chinese versus African American patients with multiple myeloma. <i>British Journal of Haematology</i> , <b>2017</b> , 176, 315-317	4.5	2
317	Systematic evaluation of circulating inflammatory markers for hepatocellular carcinoma. <i>Liver International</i> , <b>2017</b> , 37, 280-289	7.9	28
316	A multicenter randomized controlled trial (RCT) of adjuvant chemotherapy (CT) in nasopharyngeal carcinoma (NPC) with residual plasma EBV DNA (EBV DNA) following primary radiotherapy (RT) or chemoradiation (CRT).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 6002-6002	2.2	8
315	Nasopharyngeal carcinoma. <i>Lancet, The</i> , <b>2016</b> , 387, 1012-1024	40	799
314	Gemcitabine: a game changer in nasopharyngeal carcinoma. <i>Lancet, The</i> , <b>2016</b> , 388, 1853-1854	40	15
313	Epigenetic inactivation of the CpG demethylase TET1 as a DNA methylation feedback loop in human cancers. <i>Scientific Reports</i> , <b>2016</b> , 6, 26591	4.9	66
312	Applicability of albumin-bilirubin-based Japan integrated staging score in hepatitis B-associated hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2016</b> , 31, 1766-1772	4	39
311	A new prognostic histopathologic classification of nasopharyngeal carcinoma. <i>Chinese Journal of Cancer</i> , <b>2016</b> , 35, 41		56
310	Integration of albumin-bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2016</b> , 31, 1300-6	4	83
309	Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review. <i>Oral Oncology</i> , <b>2016</b> , 53, 10-6	4.4	55
308	Viral co-infections and paraproteins in HIV: effect on development of hematological malignancies. <i>Annals of Hematology</i> , <b>2016</b> , 95, 575-80	3	6
307	The association between serum folate level and toxicity of capecitabine.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3566-3566	2.2	1
306	High-density lipoprotein cholesterol as a predictor of poor survival in patients with nasopharyngeal carcinoma. <i>Oncotarget</i> , <b>2016</b> , 7, 42978-42987	3.3	22
305	Jagged 2 silencing inhibits motility and invasiveness of colorectal cancer cell lines. <i>Oncology Letters</i> , <b>2016</b> , 12, 5193-5198	2.6	6
304	Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 208-20	21.7	115
303	-induced glycolysis and apoptosis regulator promotes proliferation and invasiveness of nasopharyngeal carcinoma cells. <i>Oncology Letters</i> , <b>2015</b> , 9, 569-574	2.6	20

302	Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma. <i>Cancer</i> , <b>2015</b> , 121, 1328-38	6.4	130
301	Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 645-55	21.7	453
300	Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3356-64	2.2	410
299	Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079). <i>Investigational New Drugs</i> , <b>2015</b> , 33, 985-91	4.3	20
298	Detection of Nasopharyngeal Carcinoma by MR Imaging: Diagnostic Accuracy of MRI Compared with Endoscopy and Endoscopic Biopsy Based on Long-Term Follow-Up. <i>American Journal of Neuroradiology</i> , <b>2015</b> , 36, 2380-5	4.4	38
297	Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma. <i>Cancer</i> , <b>2015</b> , 121, 2720-9	6.4	34
296	Elucidating the prognostic significance of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese patients with metastatic colorectal cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2015</b> , 11, 160-9	1.9	11
295	Applicability of BALAD score in prognostication of hepatitis B-related hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2015</b> , 30, 1529-35	4	13
294	Human Leukocyte Antigen (HLA) A*1101-Restricted Epstein-Barr Virus-Specific T-cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma. <i>Cancer Immunology Research</i> , <b>2015</b> , 3, 1138-47	12.5	20
293	Barriers to clinical trial recruitment in head and neck cancer. <i>Oral Oncology</i> , <b>2015</b> , 51, 203-11	4.4	22
292	Characterization of the nasopharyngeal carcinoma methylome identifies aberrant disruption of key signaling pathways and methylated tumor suppressor genes. <i>Epigenomics</i> , <b>2015</b> , 7, 155-73	4.4	44
291	A phase II study of axitinib in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 6031-6031	2.2	2
290	Preclinical evaluation of PI3K inhibitor BYL719 as a single agent and its synergism in combination with cisplatin or MEK inhibitor in nasopharyngeal carcinoma (NPC). <i>American Journal of Cancer Research</i> , <b>2015</b> , 5, 1496-506	4.4	15
289	Preclinical evaluation of afatinib (BIBW2992) in esophageal squamous cell carcinoma (ESCC). <i>American Journal of Cancer Research</i> , <b>2015</b> , 5, 3588-99	4.4	11
288	A phase II clinical trial on combined axitinib and transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC): Final results and evaluation of clinical predictor for response.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4073-4073	2.2	
287	SU-E-T-727: The Application of Regularization-Based Multi-Channel Radiochromic Film Dosimetry for Patient-Specific QA of Stereotactic Body Radiation Therapy (SBRT) Treatment. <i>Medical Physics</i> , <b>2015</b> , 42, 3504-3504	4.4	
286	SU-E-T-565: Multiple Channel Radiochromic Film Calibration with Spatial Dose Gradient Regularization. <i>Medical Physics</i> , <b>2015</b> , 42, 3465-3466	4.4	
285	Epigenetic identification of receptor tyrosine kinase-like orphan receptor 2 as a functional tumor suppressor inhibiting Eatenin and AKT signaling but frequently methylated in common carcinomas. <i>Cellular and Molecular Life Sciences</i> , <b>2014</b> , 71, 2179-92	10.3	41



284	Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1204-8	10.3	138
283	The metalloprotease ADAMTS8 displays antitumor properties through antagonizing EGFR-MEK-ERK signaling and is silenced in carcinomas by CpG methylation. <i>Molecular Cancer Research</i> , <b>2014</b> , 12, 228-38	6.6	53
282	Controversies in the systemic treatment of nasopharyngeal carcinoma. <i>Oral Oncology</i> , <b>2014</b> , 50, 785-90	4.4	11
281	EpsteinBarr virus diagnostic and therapeutic opportunities in nasopharyngeal carcinoma <b>2014</b> , 167-187		
280	Epstein-Barr virus as a paradigm in nasopharyngeal cancer: from lab to clinic. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2014</b> , 149-53	7.1	18
279	A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 5009-22	12.9	94
278	Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models. <i>Cancer Letters</i> , <b>2014</b> , 343, 24-32	9.9	25
277	A novel compound 6D-offset simulating phantom and quality assurance program for stereotactic image-guided radiation therapy system. <i>Journal of Applied Clinical Medical Physics</i> , <b>2014</b> , 14, 4297	2.3	5
276	Meta-analysis of chemotherapy in nasopharyngeal carcinoma (MAC-NPC): An update on 4,798 patients.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 6022-6022	2.2	3
275	Single-nucleotide polymorphism (SNP) of excision repair cross complementation group 1 (ERCC1) in nasopharynx cancer (NPC): A companion biomarker study to Hong Kong NPC Study Group 0502 trial.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 6029-6029	2.2	1
274	Silencing of hypoxia-inducible tumor suppressor lysyl oxidase gene by promoter methylation activates carbonic anhydrase IX in nasopharyngeal carcinoma. <i>American Journal of Cancer Research</i> , <b>2014</b> , 4, 789-800	4.4	11
273	International validation of the Chinese university prognostic index for staging of hepatocellular carcinoma: a joint United Kingdom and Hong Kong study. <i>Chinese Journal of Cancer</i> , <b>2014</b> , 33, 481-91		18
272	Identifying an early indicator of drug efficacy in patients (pts) with metastatic colorectal cancer (mCRC): A prospective evaluation of circulating tumor cells (CTC), 18F-fluorodeoxyglucose positron-emission tomography (PET), and the RECIST criteria.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3582-3582	2.2	
271	Non-surgical treatment of lung cancer: personalised stereotactic ablative radiotherapy. <i>Hong Kong Medical Journal</i> , <b>2014</b> , 20, 529-36	0.7	2
270	Retrospective Study of the Incidence and Risk Factors for Hematological Malignancies in Patients with Hepatitis B Virus Infection. <i>Blood</i> , <b>2014</b> , 124, 5403-5403	2.2	1
269	A joint United Kingdom (UK) and Hong Kong (HK) study to determine prognostic factors for hepatocellular carcinoma (HCC) undergoing curative and palliative treatment.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 181-181	2.2	
268	Targeting tumor hypoxia in nasopharyngeal carcinoma. <i>Head and Neck</i> , <b>2013</b> , 35, 133-45	4.2	36
267	Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2013</b> , 71, 1417-25	3.5	12

266	The Evolving Role of Systemic Therapy in Nasopharyngeal Carcinoma: Current Strategies and Perspectives. <i>Advances in Experimental Medicine and Biology</i> , <b>2013</b> , 149-172	3.6	1
265	Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program. <i>Cancer</i> , <b>2013</b> , 119, 1838-44	6.4	112
264	FEZF2, a novel 3p14 tumor suppressor gene, represses oncogene EZH2 and MDM2 expression and is frequently methylated in nasopharyngeal carcinoma. <i>Carcinogenesis</i> , <b>2013</b> , 34, 1984-93	4.6	38
263	Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma. <i>Investigational New Drugs</i> , <b>2013</b> , 31, 1399-408	4.3	21
262	Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines. <i>Investigational New Drugs</i> , <b>2013</b> , 31, 567-75	4.3	31
261	Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines. <i>Investigational New Drugs</i> , <b>2013</b> , 31, 30-8	4.3	8
260	Consensus recommendations for management of head and neck cancer in Asian countries: a review of international guidelines. <i>Oral Oncology</i> , <b>2013</b> , 49, 872-877	4.4	52
259	Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. <i>Clinical Chemistry</i> , <b>2013</b> , 59, 211-24	5.5	373
258	An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 2208-15	12.9	108
257	Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients. <i>Cancer Research</i> , <b>2013</b> , 73, 1676-88	10.1	127
256	Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, 18761-8	11.5	267
255	Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alpha. <i>Cancer</i> , <b>2013</b> , 119, 4145-53	6.4	9
254	Phase II study of TAS-106 in patients with platinum-failure recurrent or metastatic head and neck cancer and nasopharyngeal cancer. <i>Cancer Medicine</i> , <b>2013</b> , 2, 351-9	4.8	9
253	Advanced technologies for studying circulating tumor cells at the protein level. <i>Expert Review of Proteomics</i> , <b>2013</b> , 10, 579-89	4.2	3
252	Clinical significance of frizzled homolog 3 protein in colorectal cancer patients. <i>PLoS ONE</i> , <b>2013</b> , 8, e79481	4.7	19
251	A phase IB trial of 5-azacitidine (5AC) and suberoylanilide hydroxamic acid (SAHA) in patients with metastatic or locally recurrent nasopharyngeal carcinoma (NPC) and NK-T cell lymphoma.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e17017-e17017	2.2	1
250	Randomized phase II study of erlotinib (ERL) in two different schedules with concomitant modified XELOX in the first-line treatment of metastatic colorectal cancer (mCRC): Correlation with serial serum levels of amphiregulin (AMR) and transforming growth factor receptor-alpha (TGFa).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 425-425	2.2	
249	Efficacy and toxicity of intensity-modulated radiation therapy for prostate cancer in Chinese patients. <i>Hong Kong Medical Journal</i> , <b>2013</b> , 19, 407-15	0.7	3



248	SU-E-T-94: Surface Dose Characteristics of Flattened and Flattening Filter Free Megavoltage Photon Beam. <i>Medical Physics</i> , <b>2013</b> , 40, 225-225	4.4	
247	SU-C-137-03: Inter-Machine Comparison of Volumetric Intensity Modulated Arc Therapy (VIMAT) Delivery Based On Trajectory Log Analysis. <i>Medical Physics</i> , <b>2013</b> , 40, 85-85	4.4	
246	SU-E-J-119: Geometric Accuracy Verification for Gated RapidArc Using Gated CBCT Reconstructed From Continuously Triggered KV Images. <i>Medical Physics</i> , <b>2013</b> , 40, 178-178	4.4	
245	K252a induces anoikis-sensitization with suppression of cellular migration in Epstein-Barr virus (EBV)--associated nasopharyngeal carcinoma cells. <i>Investigational New Drugs</i> , <b>2012</b> , 30, 48-58	4.3	16
244	Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. <i>Lancet Oncology</i> , <b>2012</b> , 13, 172-80	21.7	234
243	Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , <b>2012</b> , 104, 300-4	5.3	68
242	Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3361-7	2.2	146
241	CXCR6 and CCR5 localize T lymphocyte subsets in nasopharyngeal carcinoma. <i>American Journal of Pathology</i> , <b>2012</b> , 180, 1215-1222	5.8	34
240	A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma. <i>Cancer</i> , <b>2012</b> , 118, 3984-92	6.4	43
239	Use of antiviral therapy in surveillance: impact on outcome of hepatitis B-related hepatocellular carcinoma. <i>Liver International</i> , <b>2012</b> , 32, 271-8	7.9	14
238	A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma. <i>Annals of Oncology</i> , <b>2012</b> , 23, 1287-1292	10.3	91
237	The human cadherin 11 is a pro-apoptotic tumor suppressor modulating cell stemness through Wnt/βcatenin signaling and silenced in common carcinomas. <i>Oncogene</i> , <b>2012</b> , 31, 3901-12	9.2	69
236	A novel 19q13 nucleolar zinc finger protein suppresses tumor cell growth through inhibiting ribosome biogenesis and inducing apoptosis but is frequently silenced in multiple carcinomas. <i>Molecular Cancer Research</i> , <b>2012</b> , 10, 925-36	6.6	37
235	Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , <b>2012</b> , 23 Suppl 7, vii83-5	10.3	149
234	Abstract 4602: Preclinical evaluation of the AKT inhibitor MK2206 in nasopharyngeal carcinoma cell lines <b>2012</b> ,		2
233	A phase II, randomized trial (CONCERT-1) of chemoradiotherapy (CRT) with or without panitumumab (pmab) in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 5502-5502	2.2	11
232	A multicenter randomized controlled trial (RCT) of adjuvant chemotherapy (CT) in nasopharyngeal carcinoma (NPC) with residual plasma EBV DNA (EBV DNA) following primary radiotherapy (RT) or chemoradiotherapy (CRT).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 5511-5511	2.2	4
231	Predictive biomarkers of response to cetuximab in Chinese patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e14085-e14085	2.2	

230	A randomized study on lipiodal ethanol mixture (LEM) versus transarterial chemoembolization (TACE) for treatment of hepatocellular carcinoma (HCC): Report of a preplanned interim analysis.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e14528-e14528	2.2	
229	6597 POSTER A Phase II Study of Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma [a Multicenter Study of the Mayo Phase 2 Consortium (P2C) and the Cancer Therapeutics Research Group (CTRG)]. <i>European Journal of Cancer</i> , <b>2011</b> , 47, S470-S471	7.5	3
228	Current treatment of nasopharyngeal carcinoma. <i>European Journal of Cancer</i> , <b>2011</b> , 47 Suppl 3, S302-3	7.5	37
227	A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , <b>2011</b> , 98, 15-22 <sup>3</sup>	5.3	86
226	Novel therapeutic target for head and neck squamous cell carcinoma: HGF-MET signaling pathway. <i>Anti-Cancer Drugs</i> , <b>2011</b> , 22, 665-73	2.4	19
225	Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2011</b> , 26, 340-7	4	64
224	Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death. <i>Oncogene</i> , <b>2011</b> , 30, 1127-34	9.2	50
223	FGF8b oncogene mediates proliferation and invasion of Epstein-Barr virus-associated nasopharyngeal carcinoma cells: implication for viral-mediated FGF8b upregulation. <i>Oncogene</i> , <b>2011</b> , 30, 1518-30	9.2	11
222	A novel isoform of the 8p22 tumor suppressor gene DLC1 suppresses tumor growth and is frequently silenced in multiple common tumors. <i>Oncogene</i> , <b>2011</b> , 30, 1923-35	9.2	43
221	Clinical significance of CDX2-positive circulating tumour cells in colorectal cancer patients. <i>British Journal of Cancer</i> , <b>2011</b> , 104, 1000-6	8.7	18
220	Hypoxia-targeting by tirapazamine (TPZ) induces preferential growth inhibition of nasopharyngeal carcinoma cells with Chk1/2 activation. <i>Investigational New Drugs</i> , <b>2011</b> , 29, 401-10	4.3	15
219	Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma. <i>Investigational New Drugs</i> , <b>2011</b> , 29, 1123-31	4.3	25
218	Anti-invasion, anti-proliferation and anoikis-sensitization activities of lapatinib in nasopharyngeal carcinoma cells. <i>Investigational New Drugs</i> , <b>2011</b> , 29, 1241-52	4.3	16
217	Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network. <i>Supportive Care in Cancer</i> , <b>2011</b> , 19, 1125-35	3.9	32
216	Dosimetric comparison of intensity-modulated stereotactic radiotherapy with other stereotactic techniques for locally recurrent nasopharyngeal carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2011</b> , 79, 71-9	4	9
215	Primary nasopharyngeal carcinoma: diagnostic accuracy of MR imaging versus that of endoscopy and endoscopic biopsy. <i>Radiology</i> , <b>2011</b> , 258, 531-7	20.5	82
214	Eight-signature classifier for prediction of nasopharyngeal [corrected] carcinoma survival. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 4516-25	2.2	107
213	Impaired deoxyribonuclease I activity in patients with inflammatory bowel diseases. <i>Autoimmune Diseases</i> , <b>2011</b> , 2011, 945861	2.9	25

212	Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation. <i>Annals of Oncology</i> , <b>2011</b> , 22, 1280-1287	10.3	77
211	A phase I trial of recombinant modified vaccinia ankara (MVA) vaccine encoding Epstein-Barr virus (EBV) antigens.. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 2592-2592	2.2	2
210	The epigenetic modifier PRDM5 functions as a tumor suppressor through modulating WNT/ $\beta$ catenin signaling and is frequently silenced in multiple tumors. <i>PLoS ONE</i> , <b>2011</b> , 6, e27346	3.7	51
209	The significance of serum interleukin-10 on the outcome of unresectable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 205-205	2.2	1
208	Nasopharyngeal carcinoma. <i>Annals of Oncology</i> , <b>2010</b> , 21 Suppl 7, vii308-12	10.3	161
207	KRAB zinc finger protein ZNF382 is a proapoptotic tumor suppressor that represses multiple oncogenes and is commonly silenced in multiple carcinomas. <i>Cancer Research</i> , <b>2010</b> , 70, 6516-26	10.1	101
206	The tumor suppressor UCHL1 forms a complex with p53/MDM2/ARF to promote p53 signaling and is frequently silenced in nasopharyngeal carcinoma. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 2949-58	12.9	110
205	WNT5A antagonizes WNT/ $\beta$ catenin signaling and is frequently silenced by promoter CpG methylation in esophageal squamous cell carcinoma. <i>Cancer Biology and Therapy</i> , <b>2010</b> , 10, 617-24	4.6	60
204	Human papillomavirus DNA detection in menstrual blood from patients with cervical intraepithelial neoplasia and condyloma acuminatum. <i>Journal of Clinical Microbiology</i> , <b>2010</b> , 48, 709-13	9.7	7
203	Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1660-5	2.2	336
202	Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , <b>2010</b> , 21 Suppl 5, v187-9	10.3	36
201	A small molecule inhibitor of NF-kappaB, dehydroxymethylepoxyquinomicin (DHMEQ), suppresses growth and invasion of nasopharyngeal carcinoma (NPC) cells. <i>Cancer Letters</i> , <b>2010</b> , 287, 23-32	9.9	31
200	Accelerated fractionation radiotherapy and late intensification with 2 intra-arterial cisplatin infusions for locally advanced head and neck squamous cell carcinoma. <i>Head and Neck</i> , <b>2010</b> , 32, 913-20	4.2	1
199	The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines. <i>Investigational New Drugs</i> , <b>2010</b> , 28, 107-14	4.3	52
198	The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines. <i>Investigational New Drugs</i> , <b>2010</b> , 28, 413-20	4.3	55
197	Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response. <i>Investigational New Drugs</i> , <b>2010</b> , 28, 326-33	4.3	32
196	Reverse phase protein array identifies novel anti-invasion mechanisms of YC-1. <i>Biochemical Pharmacology</i> , <b>2010</b> , 79, 842-52	6	19
195	An RNA-directed nucleoside anti-metabolite, 1-(3-C-ethynyl-beta-d-ribo-pentofuranosyl)cytosine (ECyd), elicits antitumor effect via TP53-induced Glycolysis and Apoptosis Regulator (TIGAR) downregulation. <i>Biochemical Pharmacology</i> , <b>2010</b> , 79, 1772-80	6	23

194	Phase II Study of Concurrent and Adjuvant Chemotherapy with Intensity Modulated Radiation Therapy (IMRT) or Three-dimensional Conformal Radiotherapy (3D-CRT) + Bevacizumab (BV) for Locally or Regionally Advanced Nasopharyngeal Cancer (NPC)[RTOG 0615]: Preliminary Toxicity Report. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2010</b> , 78, S103-S104	4	7
193	Abstract 1638: Preclinical evaluation of the PI3K inhibitor BEZ235 in nasopharyngeal carcinoma cell lines <b>2010</b> ,		3
192	Phase I pharmacokinetics and metabolic pathway of belinostat in patients with hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 2585-2585	2.2	2
191	Long-term treatment outcome of nasopharyngeal carcinoma (NPC) using intensity-modulated radiotherapy (IMRT).. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 5582-5582	2.2	2
190	Drug Therapy for Nasopharyngeal Carcinoma: Cytotoxic and Targeted Therapy. <i>Medical Radiology</i> , <b>2010</b> , 149-160	0.2	
189	Update in antiepidermal growth factor receptor therapy in the management of metastatic colorectal cancer. <i>Journal of Oncology</i> , <b>2009</b> , 2009, 967920	4.5	6
188	Nasopharyngeal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , <b>2009</b> , 20 Suppl 4, 123-5	10.3	40
187	Clinical significance of cytokeratin 20-positive circulating tumor cells detected by a refined immunomagnetic enrichment assay in colorectal cancer patients. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 1005-1012	12.9	56
186	Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 242-9	2.2	405
185	New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 446-52	2.2	205
184	Cucurbitacin I elicits anoikis sensitization, inhibits cellular invasion and in vivo tumor formation ability of nasopharyngeal carcinoma cells. <i>Carcinogenesis</i> , <b>2009</b> , 30, 2085-94	4.6	58
183	CMTM3, located at the critical tumor suppressor locus 16q22.1, is silenced by CpG methylation in carcinomas and inhibits tumor cell growth through inducing apoptosis. <i>Cancer Research</i> , <b>2009</b> , 69, 5194-2011	10.1	84
182	Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma--correlation with excision repair cross-complementing-1 polymorphisms. <i>Annals of Oncology</i> , <b>2009</b> , 20, 1854-9	10.3	47
181	TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. <i>International Journal of Cancer</i> , <b>2009</b> , 124, 644-52	7.5	143
180	STAT3 activation contributes directly to Epstein-Barr virus-mediated invasiveness of nasopharyngeal cancer cells in vitro. <i>International Journal of Cancer</i> , <b>2009</b> , 125, 1884-93	7.5	58
179	DLEC1 is a functional 3p22.3 tumour suppressor silenced by promoter CpG methylation in colon and gastric cancers. <i>British Journal of Cancer</i> , <b>2009</b> , 100, 663-9	8.7	50
178	A broadly adaptive array of dose-constraint templates for planning of intensity-modulated radiation therapy for advanced T-stage nasopharyngeal carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2009</b> , 74, 21-8	4	7
177	Role of alpha-fetoprotein in hepatocellular carcinoma: prognostication, treatment monitoring or both?. <i>Future Oncology</i> , <b>2009</b> , 5, 889-99	3.6	26

176	52LBA Final report of NPC-9902 trial on therapeutic gain and late toxicities by concurrent-adjuvant chemotherapy and/or accelerated fractionation for T3-4N0-1M0 nasopharyngeal carcinoma. <i>European Journal of Cancer, Supplement</i> , <b>2009</b> , 7, 22	1.6	3
175	Advanced proteomic technologies for cancer biomarker discovery. <i>Expert Review of Proteomics</i> , <b>2009</b> , 6, 123-34	4.2	49
174	Management of the neck after chemoradiotherapy for head and neck cancers in Asia: consensus statement from the Asian Oncology Summit 2009. <i>Lancet Oncology, The</i> , <b>2009</b> , 10, 1086-92	21.7	45
173	Complete small bowel obstruction caused by metastasis from primary nasopharyngeal carcinoma. <i>Rare Tumors</i> , <b>2009</b> , 1, e7	1.1	2
172	Nasopharynx. <i>Medical Radiology</i> , <b>2009</b> , 57-73	0.2	
171	Epigenetic disruption of interferon-gamma response through silencing the tumor suppressor interferon regulatory factor 8 in nasopharyngeal, esophageal and multiple other carcinomas. <i>Oncogene</i> , <b>2008</b> , 27, 5267-76	9.2	65
170	Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions. <i>Cancer Science</i> , <b>2008</b> , 99, 1311-8	6.9	96
169	The prognostic significance of tumor vascular invasion and its association with plasma Epstein-Barr virus DNA, tumor volume and metabolic activity in locoregionally advanced nasopharyngeal carcinoma. <i>Oral Oncology</i> , <b>2008</b> , 44, 1067-72	4.4	17
168	Transarterial ethanol ablation of hepatocellular carcinoma with lipiodol ethanol mixture: phase II study. <i>Journal of Vascular and Interventional Radiology</i> , <b>2008</b> , 19, 95-103	2.4	18
167	Update on the management and therapeutic monitoring of advanced nasopharyngeal cancer. <i>Hematology/Oncology Clinics of North America</i> , <b>2008</b> , 22, 1267-78, x	3.1	56
166	Isolated tumor cells and circulating CK20 mRNA in pN0 colorectal cancer patients. <i>International Journal of Surgical Pathology</i> , <b>2008</b> , 16, 119-26	1.2	14
165	The impact of 18F-FDG PET/CT on assessment of nasopharyngeal carcinoma at diagnosis. <i>British Journal of Radiology</i> , <b>2008</b> , 81, 291-8	3.4	67
164	Quantitative analysis of the transrenal excretion of circulating EBV DNA in nasopharyngeal carcinoma patients. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 4809-13	12.9	50
163	EBV latent membrane proteins (LMPs) 1 and 2 as immunotherapeutic targets: LMP-specific CD4+ cytotoxic T cell recognition of EBV-transformed B cell lines. <i>Journal of Immunology</i> , <b>2008</b> , 180, 1643-54	5.3	49
162	A novel application of plasma and cerebrospinal fluid level of epstein barr virus DNA in the diagnosis of leptomenigeal metastasis from nasopharyngeal carcinoma. A case report. <i>Oncology</i> , <b>2008</b> , 74, 119-22	3.6	2
161	Nasopharyngeal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , <b>2008</b> , 19 Suppl 2, ii81-2	10.3	9
160	Persistent aberrations in circulating DNA integrity after radiotherapy are associated with poor prognosis in nasopharyngeal carcinoma patients. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 4141-5	12.9	63
159	WNT5A exhibits tumor-suppressive activity through antagonizing the Wnt/beta-catenin signaling, and is frequently methylated in colorectal cancer. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 55-61	12.9	166



158	Plasma osteopontin, hypoxia, and response to radiotherapy in nasopharyngeal cancer. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 7080-7	12.9	31
157	OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation. <i>PLoS ONE</i> , <b>2008</b> , 3, e2990	3.7	84
156	The KRAB domain-containing zinc finger protein ZNF382 is a potent tumor suppressor with frequent epigenetic inactivation in nasopharyngeal, esophageal and other carcinomas. <i>Cell Biology International</i> , <b>2008</b> , 32, S5-S5	4.5	
155	A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells. <i>Investigational New Drugs</i> , <b>2008</b> , 26, 169-73	4.3	123
154	CD4 and CD8 T cell responses to tumour-associated Epstein-Barr virus antigens in nasopharyngeal carcinoma patients. <i>Cancer Immunology, Immunotherapy</i> , <b>2008</b> , 57, 963-75	7.4	35
153	A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2008</b> , 62, 59-64	3.5	67
152	Inhibition of apoptosis in human laryngeal cancer cells by E6 and E7 oncoproteins of human papillomavirus 16. <i>Journal of Cellular Biochemistry</i> , <b>2008</b> , 103, 1125-43	4.7	13
151	Epigenetic identification of ubiquitin carboxyl-terminal hydrolase L1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors. <i>Hepatology</i> , <b>2008</b> , 48, 508-18	11.2	119
150	A split-organ delineation approach for dose optimisation for intensity-modulated radiotherapy for advanced T-stage nasopharyngeal carcinoma. <i>Clinical Oncology</i> , <b>2008</b> , 20, 134-41	2.8	10
149	Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy. <i>Annals of Surgical Oncology</i> , <b>2008</b> , 15, 1008-14	3.1	103
148	Therapeutic vaccination with modified vaccinia Ankara (MVA) encoding Epstein-Barr virus (EBV) target antigens in EBV+ nasopharyngeal carcinoma (NPC). <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 3052-3052	2.2	2
147	A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy (IMRT) in locoregionally advanced nasopharyngeal carcinoma (NPC) with correlation using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 6055-6055	2.2	10
146	Accomplishments in 2007 in the management of hepatobiliary cancers. <i>Gastrointestinal Cancer Research: GCR</i> , <b>2008</b> , 2, S25-31		5
145	Proteomic comparison of nasopharyngeal cancer cell lines C666-1 and NP69 identifies down-regulation of annexin II and beta2-tubulin for nasopharyngeal carcinoma. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2008</b> , 132, 675-83	5	27
144	Identification of 5-fluorouracil response proteins in colorectal carcinoma cell line SW480 by two-dimensional electrophoresis and MALDI-TOF mass spectrometry. <i>Oncology Reports</i> , <b>2008</b> , 20, 89-98	3.5	41
143	Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy. <i>Hepatology</i> , <b>2007</b> , 45, 1382-9	11.2	55
142	Adjuvant chemoradiation for gastric cancer: experience in the Chinese population. <i>Clinical Oncology</i> , <b>2007</b> , 19, 333-40	2.8	9
141	Nasopharyngeal cancers: which method should be used to measure these irregularly shaped tumors on cross-sectional imaging?. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2007</b> , 69, 148-54	4	25



140	Dosimetric comparison between 2-dimensional radiation therapy and intensity modulated radiation therapy in treatment of advanced T-stage nasopharyngeal carcinoma: to treat less or more in the planning organ-at-risk volume of the brainstem and spinal cord. <i>Medical Dosimetry</i> , <b>2007</b> , 32, 263-70	1.3	47
139	The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation. <i>Oncogene</i> , <b>2007</b> , 26, 934-44	9.2	109
138	Epigenetic identification of ADAMTS18 as a novel 16q23.1 tumor suppressor frequently silenced in esophageal, nasopharyngeal and multiple other carcinomas. <i>Oncogene</i> , <b>2007</b> , 26, 7490-8	9.2	91
137	The tumor suppressor Wnt inhibitory factor 1 is frequently methylated in nasopharyngeal and esophageal carcinomas. <i>Laboratory Investigation</i> , <b>2007</b> , 87, 644-50	5.9	84
136	Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies. <i>British Journal of Haematology</i> , <b>2007</b> , 136, 829-32	4.5	50
135	Cyclooxygenase-2 expression in advanced nasopharyngeal carcinoma--a prognostic evaluation and correlation with hypoxia inducible factor 1alpha and vascular endothelial growth factor. <i>Oral Oncology</i> , <b>2007</b> , 43, 373-8	4.4	23
134	The effect of centrifugation on circulating mRNA quantitation opens up a new scenario in expression profiling from patients with metastatic colorectal cancer. <i>Clinical Biochemistry</i> , <b>2007</b> , 40, 1277-84	3.5	6
133	Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG). <i>Cancer Chemotherapy and Pharmacology</i> , <b>2007</b> , 59, 295-300	3.5	13
132	Tumor-specific methylation of the 8p22 tumor suppressor gene DLC1 is an epigenetic biomarker for Hodgkin, nasal NK/T-cell and other types of lymphomas. <i>Epigenetics</i> , <b>2007</b> , 2, 15-21	5.7	25
131	Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 4873-9	2.2	567
130	Epigenetic silencing of a Ca(2+)-regulated Ras GTPase-activating protein RASAL defines a new mechanism of Ras activation in human cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2007</b> , 104, 12353-8	11.5	105
129	Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. <i>Expert Reviews in Molecular Medicine</i> , <b>2007</b> , 9, 1-24	6.7	236
128	Sequential chemotherapy with combination irinotecan and cisplatin followed by docetaxel for treatment-naïve patients with advanced non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, 838-44	8.9	3
127	Genome-wide expression analysis using microarray identified complex signaling pathways modulated by hypoxia in nasopharyngeal carcinoma. <i>Cancer Letters</i> , <b>2007</b> , 253, 74-88	9.9	46
126	Radiological, pathological and DNA remission in recurrent metastatic nasopharyngeal carcinoma. <i>BMC Cancer</i> , <b>2006</b> , 6, 259	4.8	6
125	Effects of patupilone (epothilone B; EPO906), a novel chemotherapeutic agent, in hepatocellular carcinoma: an in vitro study. <i>Oncology</i> , <b>2006</b> , 71, 292-6	3.6	19
124	Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. <i>Annals of Oncology</i> , <b>2006</b> , 17, 1083-9	10.3	85
123	Transcriptional profiling of tumor biopsies in oncology trials--a window of opportunity for evaluating new drugs in nasopharyngeal cancer?. <i>Annals of Oncology</i> , <b>2006</b> , 17, 1611-3	10.3	1

122	Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays. <i>Journal of General Virology</i> , <b>2006</b> , 87, 2885-2890	4.9	106
121	Reduced plasma RNA integrity in nasopharyngeal carcinoma patients. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 2512-6	12.9	23
120	Nuclear beta-catenin and Ki-67 expression in choriocarcinoma and its pre-malignant form. <i>Journal of Clinical Pathology</i> , <b>2006</b> , 59, 387-92	3.9	12
119	CD4+ T-cell responses to Epstein-Barr virus nuclear antigen EBNA1 in Chinese populations are highly focused on novel C-terminal domain-derived epitopes. <i>Journal of Virology</i> , <b>2006</b> , 80, 8263-6	6.6	19
118	Systemic treatment strategies and therapeutic monitoring for advanced nasopharyngeal carcinoma. <i>Expert Review of Anticancer Therapy</i> , <b>2006</b> , 6, 383-94	3.5	37
117	Clinical studies of immunomodulatory activities of Yunzhi-Danshen in patients with nasopharyngeal carcinoma. <i>Journal of Alternative and Complementary Medicine</i> , <b>2006</b> , 12, 771-6	2.4	32
116	An unusual cause of superior vena cava obstruction. <i>Thorax</i> , <b>2006</b> , 61, 182	7.3	3
115	Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 5414-8	2.2	285
114	Pharmacoproteomics study of cetuximab in nasopharyngeal carcinoma. <i>Journal of Proteome Research</i> , <b>2006</b> , 5, 3260-7	5.6	18
113	Dose-response relationship of nasopharyngeal carcinoma above conventional tumoricidal level: a study by the Hong Kong nasopharyngeal carcinoma study group (HKNPCSG). <i>Radiotherapy and Oncology</i> , <b>2006</b> , 79, 27-33	5.3	58
112	Study of serum haptoglobin and its glycoforms in the diagnosis of hepatocellular carcinoma: a glycoproteomic approach. <i>Journal of Proteome Research</i> , <b>2006</b> , 5, 2691-700	5.6	131
111	Chemotherapy as an adjunct to radiotherapy in locally advanced nasopharyngeal carcinoma. <i>The Cochrane Library</i> , <b>2006</b> , CD004329	5.2	34
110	Automated extraction protocol for quantification of SARS-coronavirus RNA in serum: an evaluation study. <i>BMC Infectious Diseases</i> , <b>2006</b> , 6, 20	4	4
109	Case of chlorambucil-induced seizure. <i>Internal Medicine Journal</i> , <b>2006</b> , 36, 683-4	1.6	2
108	Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. <i>Oncogene</i> , <b>2006</b> , 25, 1070-80	9.2	223
107	Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2006</b> , 64, 47-56	4	494
106	Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2006</b> , 66, 142-51	4	128
105	Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2006</b> , 66, 714-20	4	84

104	Celecoxib induces dose dependent growth inhibition in nasopharyngeal carcinoma cell lines independent of cyclooxygenase-2 expression. <i>Biomedicine and Pharmacotherapy</i> , <b>2005</b> , 59 Suppl 2, S268-75	7.5	14
103	Nuclear beta-catenin expression is rare and its potential association with short survival in colorectal signet-ring cell carcinoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , <b>2005</b> , 13, 248-51	1.9	8
102	Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2005</b> , 28, 379-84	2.7	51
101	Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group. <i>Medical Oncology</i> , <b>2005</b> , 22, 303-12	3.7	49
100	Survival outcome of patients with nasopharyngeal carcinoma with first local failure: a study by the Hong Kong Nasopharyngeal Carcinoma Study Group. <i>Head and Neck</i> , <b>2005</b> , 27, 397-405	4.2	126
99	Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma. <i>Cancer</i> , <b>2005</b> , 103, 22-31	6.4	100
98	Correlation and prognostic significance of beta-galactoside alpha-2,6-sialyltransferase and serum monosialylated alpha-fetoprotein in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , <b>2005</b> , 11, 6701-6	5.6	15
97	Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. <i>Journal of the National Cancer Institute</i> , <b>2005</b> , 97, 536-9	9.7	371
96	Delayed radiation myelopathy after concurrent chemoradiation for hypopharyngeal-esophageal carcinoma. <i>Acta Oncologica</i> , <b>2005</b> , 44, 177-9	3.2	2
95	Comparison of protocols for extracting circulating DNA and RNA from maternal plasma. <i>Clinical Chemistry</i> , <b>2005</b> , 51, 2209-10	5.5	10
94	Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 3568-76	2.2	233
93	Phase II randomized study comparing the toxicity profile of gemcitabine plus cisplatin with gemcitabine plus oral etoposide in the treatment of advanced non-small cell lung cancer. <i>Oncology</i> , <b>2005</b> , 68, 485-92	3.6	14
92	Investigation into the origin and tumoral mass correlation of plasma Epstein-Barr virus DNA in nasopharyngeal carcinoma. <i>Clinical Chemistry</i> , <b>2005</b> , 51, 2192-5	5.5	39
91	An intensive surveillance program detected a high incidence of hepatocellular carcinoma among hepatitis B virus carriers with abnormal alpha-fetoprotein levels or abdominal ultrasonography results. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 8041-7	2.2	34
90	Head and neck cancer: treatment of nasopharyngeal cancer. <i>Annals of Oncology</i> , <b>2005</b> , 16 Suppl 2, ii265-8	0.3	5
89	A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. <i>Journal of the National Cancer Institute</i> , <b>2005</b> , 97, 1532-8	9.7	490
88	Subcutaneous amifostine for reduction of radiation xerostomia in nasopharynx cancer: A prospective randomised study. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 8043-8043	2.2	2
87	Antitumor effect and enhancement of cytotoxic drug activity by cetuximab in nasopharyngeal carcinoma cells. <i>In Vivo</i> , <b>2005</b> , 19, 237-45	2.3	58

86	False-negative rate of abdominal sonography for detecting hepatocellular carcinoma in patients with hepatitis B and elevated serum alpha-fetoprotein levels. <i>American Journal of Roentgenology</i> , <b>2004</b> , 183, 453-8	5.4	11
85	Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody. <i>Clinical Chemistry</i> , <b>2004</b> , 50, 339-45	5.5	86
84	Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 1373-81	2.2	114
83	Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 4456-62	2.2	544
82	Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. <i>Annals of Oncology</i> , <b>2004</b> , 15, 1661-6	10.3	132
81	Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 3053-60	2.2	103
80	Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nonnasopharyngeal head and neck carcinomas. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 1726-32	12.9	14
79	A phase I safety and pharmacokinetic study of OGT 719 in patients with liver cancer. <i>Acta Oncologica</i> , <b>2004</b> , 43, 245-51	3.2	6
78	Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 927-34	2.2	226
77	Effect of age and disease on taste perception. <i>Journal of Pain and Symptom Management</i> , <b>2004</b> , 28, 28-34	3.8	40
76	Pathogenesis and treatment of nasopharyngeal carcinoma. <i>Seminars in Oncology</i> , <b>2004</b> , 31, 794-801	5.5	44
75	Technical evaluation of MALDI-TOF mass spectrometry for quantitative proteomic profiling matrix formulation and application. <i>Clinical Proteomics</i> , <b>2004</b> , 1, 259-270	5	13
74	Serum proteomic pattern for predicting recurrence of undifferentiated nasopharyngeal carcinoma after radiotherapy. <i>Clinical Proteomics</i> , <b>2004</b> , 1, 365-373	5	2
73	Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2004</b> , 60, 1440-50	4	431
72	Lung metastasis alone in nasopharyngeal carcinoma: a relatively favorable prognostic group. A study by the Hong Kong Nasopharyngeal Carcinoma Study Group. <i>Cancer</i> , <b>2004</b> , 101, 300-6	6.4	146
71	Prospective validation of serum CYFRA 21-1, beta-2-microglobulin, and ferritin levels as prognostic markers in patients with nonmetastatic nasopharyngeal carcinoma undergoing radiotherapy. <i>Cancer</i> , <b>2004</b> , 101, 776-81	6.4	18
70	Distribution of cell-free and cell-associated Epstein-Barr virus (EBV) DNA in the blood of patients with nasopharyngeal carcinoma and EBV-associated lymphoma. <i>Clinical Chemistry</i> , <b>2004</b> , 50, 1842-5	5.5	12
69	Radiotherapy for nasopharyngeal carcinoma--transition from two-dimensional to three-dimensional methods. <i>Radiotherapy and Oncology</i> , <b>2004</b> , 73, 163-72	5.3	53

68	Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. <i>Clinical Chemistry</i> , <b>2003</b> , 49, 752-60	5.5	208
67	Nonplatinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer. <i>Clinical Pulmonary Medicine</i> , <b>2003</b> , 10, 143-153	0.3	
66	Nasopharyngeal cancer. <i>Cancer Treatment and Research</i> , <b>2003</b> , 114, 275-93	3.5	11
65	Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. <i>Cancer</i> , <b>2003</b> , 98, 288-91	6.4	129
64	Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma--a prospective study. <i>Head and Neck</i> , <b>2003</b> , 25, 864-72	4.2	146
63	A prospective study of pre-treatment cell kinetics and clinical outcome in nasopharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , <b>2003</b> , 69, 53-62	5.3	8
62	Quantitative analysis of pleural fluid cell-free DNA as a tool for the classification of pleural effusions. <i>Clinical Chemistry</i> , <b>2003</b> , 49, 740-5	5.5	27
61	HLA-A11-restricted epitope polymorphism among Epstein-Barr virus strains in the highly HLA-A11-positive Chinese population: incidence and immunogenicity of variant epitope sequences. <i>Journal of Virology</i> , <b>2003</b> , 77, 11507-16	6.6	29
60	Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. <i>Cancer Research</i> , <b>2003</b> , 63, 2028-32	10.1	151
59	Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 3254-9	12.9	109
58	Disparity of sensitivities in detection of radiation-naïve and postirradiation recurrent nasopharyngeal carcinoma of the undifferentiated type by quantitative analysis of circulating Epstein-Barr virus DNA1,2. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 3431-4	12.9	42
57	Treatment strategy and clinical experience. <i>Seminars in Cancer Biology</i> , <b>2002</b> , 12, 497-504	12.7	21
56	Frequency of Epstein-Barr virus-specific cytotoxic T lymphocytes in the blood of Southern Chinese blood donors and nasopharyngeal carcinoma patients. <i>Journal of Medical Virology</i> , <b>2002</b> , 67, 359-63	19.7	35
55	A Phase I-II study of sequential administration of topotecan and oral etoposide (topoisomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma. <i>Cancer</i> , <b>2002</b> , 95, 1511-9	6.4	24
54	Expression of epidermal growth factor receptor in head and neck cancers correlates with clinical progression: a multicentre immunohistochemical study in the Asia-Pacific region. <i>Histopathology</i> , <b>2002</b> , 41, 144-51	7.3	47
53	Nasopharyngeal carcinoma. <i>Annals of Oncology</i> , <b>2002</b> , 13, 1007-15	10.3	233
52	Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. <i>Journal of the National Cancer Institute</i> , <b>2002</b> , 94, 1614-9	9.7	315
51	Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 2038-44	2.2	382



50	Phase II study of docetaxel and epirubicin in Chinese patients with metastatic breast cancer. <i>Anti-Cancer Drugs</i> , <b>2002</b> , 13, 655-62	2.4	9
49	Differential expression of the suppressor PML and Ki-67 identifies three subtypes of human nasopharyngeal carcinoma. <i>European Journal of Cancer</i> , <b>2002</b> , 38, 1600-6	7.5	8
48	Quantification and Utility of Monosialylated $\alpha$ -Fetoprotein in the Diagnosis of Hepatocellular Carcinoma with Nondiagnostic Serum Total $\alpha$ -Fetoprotein. <i>Clinical Chemistry</i> , <b>2002</b> , 48, 1021-1027	5.5	50
47	Quantification and utility of monosialylated alpha-fetoprotein in the diagnosis of hepatocellular carcinoma with nondiagnostic serum total alpha-fetoprotein. <i>Clinical Chemistry</i> , <b>2002</b> , 48, 1021-7	5.5	8
46	Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. <i>Clinical Cancer Research</i> , <b>2002</b> , 8, 2595-604	12.9	210
45	Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma. <i>Cancer</i> , <b>2001</b> , 91, 2369-2377	6.4	20
44	The use of brush cytology and directed biopsies for the detection of nasopharyngeal carcinoma and precursor lesions. <i>Head and Neck</i> , <b>2001</b> , 23, 637-45	4.2	9
43	Quantitative correlation of cytokeratin 19 mRNA level in peripheral blood with disease stage and metastasis in breast cancer patients: potential prognostic implications. <i>International Journal of Oncology</i> , <b>2001</b> , 18, 633-8	1	5
42	Application of classification tree and neural network algorithms to the identification of serological liver marker profiles for the diagnosis of hepatocellular carcinoma. <i>Oncology</i> , <b>2001</b> , 61, 275-83	3.6	29
41	Quantitative relationship of the circulating tumor burden assessed by reverse transcription-polymerase chain reaction for cytokeratin 19 mRNA in peripheral blood of colorectal cancer patients with Dukes stage, serum carcinoembryonic antigen level and tumor progression. <i>Cancer Letters</i> , <b>2001</b> , 162, 65-73	9.9	40
40	The cost of palliative care for hepatocellular carcinoma in Hong Kong. <i>Pharmacoeconomics</i> , <b>2001</b> , 19, 947-53	4.4	21
39	A phase II study of gemcitabine plus oral etoposide in the treatment of patients with advanced nonsmall cell lung carcinoma. <i>Cancer</i> , <b>2000</b> , 89, 543-550	6.4	17
38	Final report of a randomized trial on altered-fractionated radiotherapy in nasopharyngeal carcinoma prematurely terminated by significant increase in neurologic complications. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2000</b> , 48, 1311-22	4	103
37	Novel intertypic recombinants of Epstein-Barr virus in the Chinese population. <i>Journal of Virology</i> , <b>2000</b> , 74, 1544-8	6.6	55
36	CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells. <i>Journal of Immunology</i> , <b>2000</b> , 165, 573-82	5.3	96
35	Longitudinal colour Doppler study of superficial lymph nodes in non-Hodgkin's lymphoma patients on chemotherapy. <i>Clinical Radiology</i> , <b>2000</b> , 55, 110-3	2.9	13
34	Clinical outcomes of post-operative locoregional radiotherapy in pre-menopausal and post-menopausal Chinese women with breast cancer. <i>Radiotherapy and Oncology</i> , <b>2000</b> , 54, 201-8	5.3	4
33	Utilization and monitoring of aminoglycosides in oncology patients at a Hong Kong government hospital. <i>Annals of Pharmacotherapy</i> , <b>1999</b> , 33, 646-9	2.9	2



32	Enhancement of local control in locally advanced node-positive nasopharyngeal carcinoma by adjunctive chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>1999</b> , 43, 261-71	4	46
31	Netilmicin pharmacokinetics in Hong Kong Chinese cancer patients. <i>British Journal of Clinical Pharmacology</i> , <b>1999</b> , 48, 33-5	3.8	1
30	Phase II studies with DaunoXome in patients with nonresectable hepatocellular carcinoma: clinical and pharmacokinetic outcomes. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1999</b> , 44, 124-30	3.5	20
29	A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1999</b> , 44, 307-11	3.5	42
28	Increased incidence of tongue cancer after primary radiotherapy for nasopharyngeal carcinoma--the possibility of radiation carcinogenesis. <i>European Journal of Cancer</i> , <b>1999</b> , 35, 219-25	7.5	18
27	Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. <i>Lancet, The</i> , <b>1999</b> , 353, 797-801	4.0	373
26	The role of chemotherapy in the management of nasopharyngeal carcinoma. <i>Cancer</i> , <b>1998</b> , 82, 1003-12	6.4	80
25	Application of the international prognostic index in a study of Chinese patients with non-Hodgkin's lymphoma and a high incidence of primary extranodal lymphoma. <i>Cancer</i> , <b>1998</b> , 82, 2439-48	6.4	18
24	Multimodality treatment of primary lymphoepithelioma-like carcinoma of the lung. <i>Cancer</i> , <b>1998</b> , 83, 925-9	6.4	46
23	Phase II study of Temodal in the treatment of patients with advanced nasopharyngeal carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1998</b> , 42, 247-9	3.5	10
22	How successful is high-dose (> or = 60 Gy) reirradiation using mainly external beams in salvaging local failures of nasopharyngeal carcinoma?. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>1998</b> , 40, 897-913	4	170
21	A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma. <i>European Journal of Cancer</i> , <b>1998</b> , 34, 2027-31	7.5	88
20	Controversies in the management of locoregionally advanced nasopharyngeal carcinoma. <i>Current Opinion in Oncology</i> , <b>1998</b> , 10, 219-25	4.2	18
19	Transdermal fentanyl for severe cancer-related pain. <i>Palliative Medicine</i> , <b>1997</b> , 11, 233-9	5.5	19
18	Carbamazepine-induced lymphadenopathy mimicking Ki-1 (CD30+) T-cell lymphoma. <i>Pathology</i> , <b>1997</b> , 29, 64-6	1.6	9
17	Assessment of proliferating cell nuclear antigen in nasopharyngeal carcinoma tissue and its relation to clinical findings. <i>Oral Oncology</i> , <b>1997</b> , 33, 13-8	4.4	7
16	Nasal lymphoma: results of local radiotherapy with or without chemotherapy. <i>Head and Neck</i> , <b>1997</b> , 19, 251-9	4.2	17
15	In vitro uptake of bromodeoxyuridine by human nasopharyngeal carcinoma (NPC) and its relation to clinical findings. <i>European Journal of Cancer Part B, Oral Oncology</i> , <b>1996</b> , 32B, 50-4		1

14	Thoracoscopic Talc Insufflation Versus Talc Slurry for Symptomatic Malignant Pleural Effusion. <i>Annals of Thoracic Surgery</i> , <b>1996</b> , 62, 1655-1658	2.7	171
13	Early tumour response and treatment toxicity after hyperfractionated radiotherapy in nasopharyngeal carcinoma. <i>British Journal of Radiology</i> , <b>1996</b> , 69, 241-8	3.4	24
12	Primary mediastinal malignant germ cell tumour. Single institution experience in Chinese patients and correlation with specific alpha-fetoprotein bands. <i>Acta Oncologica</i> , <b>1996</b> , 35, 221-7	3.2	3
11	Phase II study of the combination of carboplatin and 5-fluorouracil in metastatic nasopharyngeal carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1996</b> , 38, 466-70	3.5	42
10	Rapid healing of an indolent leg ulcer with topical rhGM-CSF. <i>Australian and New Zealand Journal of Medicine</i> , <b>1996</b> , 26, 420-1		9
9	Isoelectric focusing of alphafetoprotein in patients with hepatocellular carcinoma--frequency of specific banding patterns at non-diagnostic serum levels. <i>British Journal of Cancer</i> , <b>1996</b> , 73, 985-8	8.7	18
8	A retrospective study of the use of cisplatin-5-fluorouracil neoadjuvant chemotherapy in cervical-node-positive nasopharyngeal carcinoma (NPC). <i>European Journal of Cancer Part B, Oral Oncology</i> , <b>1995</b> , 31B, 373-9		9
7	Video-assisted thoracoscopic wedge resections of pulmonary metastatic osteosarcoma: should it be performed?. <i>ANZ Journal of Surgery</i> , <b>1995</b> , 65, 737-9	1	17
6	Germ cell tumors express a specific alpha-fetoprotein variant detectable by isoelectric focusing. <i>Cancer</i> , <b>1995</b> , 75, 1663-8	6.4	15
5	A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>1995</b> , 33, 569-77	4	232
4	Hypersensitivity to dexamethasone. <i>BMJ: British Medical Journal</i> , <b>1993</b> , 306, 109		2
3	Pseudomembranous colitis complicating chemotherapy. <i>Lancet, The</i> , <b>1992</b> , 339, 192-3	40	8
2	Nasopharynx512-523		
1	Nasopharynx512-523		